This suggests that long-term inhibition of p110α in the clinic might not have a detrimental effect on glucose metabolism, as would be expected based on the impact of p110α inactivation in young mice (Foukas et al, 2006) and the negative impact of acute class I PI3K inhibition in human cancer patients in phase I/II trials (Bendell et al, 2012). Here, PIK3CA is linked to cancer.